Evaluation of a New HTLV‐I/II Polymerase Chain Reaction

Vrielink, H.; Zaaijer, Hans L.; Cuypers, H. T. M.; Poel, C.L. van der; Woerdeman, M. W.; Lelie, P. N.; Winkel, C; Reesink, H. W.

doi:10.1046/j.1423-0410.1997.7230144.x

Cited by 18 publications

(11 citation statements)

References 25 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the new version of the WB assay, WB2.4, has substantially decreased the high rate of false-positive results usually obtained by WB with WB2.3 (4,8), a large number of indeterminate results are still observed due to reactivity with bands other than GD21. All WB-indeterminate and nontypeable but positive samples were negative by PCR with both sets of primers (Table 1), in agreement with other studies that have shown a low percentage of HTLV infections among individuals whose samples have indeterminate results by WB and these reactivity patterns (10,11). Four samples were positive only for tax primers.…”

Section: Discussionsupporting

confidence: 90%

Evaluation of the INNO-LIA HTLV I/II Assay for Confirmation of Human T-Cell Leukemia Virus-Reactive Sera in Blood Bank Donations

Sabino

Zrein²,

Taborda

et al. 1999

J Clin Microbiol

View full text Add to dashboard Cite

We have evaluated a new serological confirmatory test (INNO-LIA HTLV I/II Ab [INNO-LIA]) for human T-cell leukemia virus (HTLV) using a large collection of samples from Brazilian blood donors (São Paulo region) and compared the results with those obtained by Western blotting (WB) tests (WB2.3 and WB2.4). Blood donations were initially screened by enzyme-linked immunosorbent assays (ELISAs) based on viral lysates, and repeatedly reactive samples were further tested by WB2.3. When available, samples were also tested by PCR, two additional ELISAs based on recombinant antigens (recombinant ELISAs), a new-generation WB assay (WB2.4), and the INNO-LIA. Of the 18,169 samples tested, 292 (1.61%) were repeatedly reactive in the ELISAs (viral lysate based) and were further tested by WB2.3; 97 were positive (19 that were typed as HTLV type I [HTLV-I], 12 that were typed as HTLV type II [HTLV-II], and 66 that were nontypeable), 17 were negative, and 178 had indeterminate results. Of the samples with indeterminate results, 172 were tested by INNO-LIA, which could resolve 153 samples as negative. Regarding the positive samples, WB2.3 and INNO-LIA produced concordant results for all HTLV-I-positive samples, whereas for HTLV-II they agreed for 10 of 12 samples; the 2 samples with discordant results were considered to be positive for HTLV-II by WB with WB2.3 but negative for HTLV-II by INNO-LIA and the two recombinant ELISAs. Furthermore, of the 66 nontypeable samples, 60 underwent testing by INNO-LIA; 54 turned out to be negative by the latter test as well as by recombinant ELISAs. In conclusion, the new serological confirmatory assay for HTLV (INNO-LIA HTLV I/II Ab) resolved the results for the majority of the indeterminate and positive-untypeable samples frequently observed by WB assays.

show abstract

Section: Discussionsupporting

confidence: 90%

Evaluation of the INNO-LIA HTLV I/II Assay for Confirmation of Human T-Cell Leukemia Virus-Reactive Sera in Blood Bank Donations

Sabino

Zrein²,

Taborda

et al. 1999

J Clin Microbiol

View full text Add to dashboard Cite

show abstract

“…There have been many published studies on the potential role of HTLV polymerase chain reaction (PCR) in blood donor screening algorithms; 17‐24 even so, no such PCR assay has been widely used or validated in the context of blood donation screening or confirmatory testing. An early report on HTLV serologic false negativity and enhanced detection by PCR has never been reproduced 17,18,20 .…”

Section: Discussionmentioning

confidence: 99%

Human T‐lymphotropic virus antibody screening of blood donors: rates of false‐positive results and evaluation of a potential donor reentry algorithm

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Others have reported the use of PCR for the detection of HTLV using primers derived from the gag, pol and env region of the HTLV‐I genome [12][13], and have found them useful in confirming and resolving inconclusive serological results. However, it has been reported that there may exist a carrier state [8], in which the Tax gene was detected in 8·6% of low‐risk New York City blood donors who were serologically negative (‘Tax’ only).…”

Section: Discussionmentioning

confidence: 99%

Detection of HTLV‐I and ‐II in Scottish blood donor samples and archive donations

et al. 2006

View full text Add to dashboard Cite

show abstract

Evaluation of a New HTLV‐I/II Polymerase Chain Reaction

Abstract: The Roche Amplicor HTLV-I/II test is a simple test, suitable for the confirmation of HTLV-I and-II infection in individuals with indeterminate or positive WB patterns.

Cited by 18 publications

References 25 publications

Evaluation of the INNO-LIA HTLV I/II Assay for Confirmation of Human T-Cell Leukemia Virus-Reactive Sera in Blood Bank Donations

Evaluation of the INNO-LIA HTLV I/II Assay for Confirmation of Human T-Cell Leukemia Virus-Reactive Sera in Blood Bank Donations

Human T‐lymphotropic virus antibody screening of blood donors: rates of false‐positive results and evaluation of a potential donor reentry algorithm

Detection of HTLV‐I and ‐II in Scottish blood donor samples and archive donations

Contact Info

Product

Resources

About